H-G Schaible. Show Affiliations »
Abstract
Entities: Disease
Mesh： See more » Analgesics/adverse effectsAnalgesics/therapeutic useAntibodies, Monoclonal/adverse effectsAntibodies, Monoclonal/therapeutic useAntibodies, Monoclonal, HumanizedArthritis, Rheumatoid/drug therapyArthritis, Rheumatoid/geneticsArthritis, Rheumatoid/physiopathologyClinical Trials, Phase III as TopicDiffusion of InnovationDisease ProgressionDrug-Related Side Effects and Adverse ReactionsEarly Termination of Clinical TrialsHumansHyperalgesia/geneticsHyperalgesia/physiopathologyNerve Growth Factor/antagonists & inhibitorsNerve Growth Factor/physiologyNociceptors/drug effectsOsteoarthritis/drug therapyOsteoarthritis/geneticsOsteoarthritis/physiopathologyRNA, Messenger/geneticsReceptor, trkA/geneticsRisk FactorsUp-Regulation/genetics
Substances： See more » AnalgesicsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedNGF protein, humanRNA, MessengerNerve Growth FactorReceptor, trkAtanezumab
Year: 2010 PMID： 21057818 DOI： 10.1007/s00482-010-0993-0
Source DB: PubMed Journal: Schmerz ISSN： 0932-433X Impact factor: 1.107